

## NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

## Single Technology Appraisal (STA)

## Bevacizumab in combination with oxaliplatin and either 5FU or capecitabine for the treatment of metastatic colorectal cancer

## Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Roche Products (bevacizumab)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Afiya Trust</li> <li>• Age Concern England</li> <li>• Beating Bowel Cancer</li> <li>• Black Health Agency (BHA)</li> <li>• Bowel Cancer UK</li> <li>• CANCERactive</li> <li>• Cancerbackup</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Cancer Voices</li> <li>• Chinese National Healthy Living Centre</li> <li>• Colostomy Association</li> <li>• Confederation of Indian Organisations</li> <li>• CORE (Digestive Disorders Foundation)</li> <li>• Counsel and Care</li> <li>• Equalities National Council</li> <li>• Helen Rollason Heal Cancer Charity</li> <li>• Help the Aged</li> <li>• IA: Ileostomy and Internal Pouch Support Group</li> <li>• Lynn's Bowel Cancer Campaign</li> <li>• Macmillan Cancer Support</li> <li>• Maggie's Centres</li> <li>• Marie Curie Cancer Care</li> <li>• Muslim Council of Great Britain</li> <li>• Muslim Health Network</li> <li>• National Cancer Alliance</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Age Concern Cymru</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Cancer Care Cymru</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Public Health Service for Wales</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• NHS Purchasing and Supply Agency</li> <li>• NHS Quality Improvement Scotland</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> <li>• Actavis UK (oxaliplatin)</li> <li>• Generics (calcium folinate)</li> <li>• Hospira (calcium folinate, fluorouracil, oxaliplatin)</li> <li>• Medac UK (disodium folinate, fluorouracil, oxaliplatin)</li> <li>• Merck Serono (tegafur with uracil)</li> <li>• Pfizer (irinotecan)</li> <li>• Roche Products (capecitabine)</li> <li>• Sanofi-Aventis (oxaliplatin)</li> <li>• Teva (calcium folinate, oxaliplatin)</li> <li>• Wockhardt (calcium folinate)</li> <li>• Wyeth Pharmaceuticals (calcium</li> </ul>

National Institute for Health and Clinical Excellence

Matrix for the appraisal of bevacizumab in combination with oxaliplatin and either 5FU or capecitabine for the treatment of metastatic colorectal cancer

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• National Council for Palliative Care</li> <li>• Ostomy Lifestyle Centre</li> <li>• Pelican Cancer Foundation</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Sue Ryder Care</li> <li>• Teenage Cancer Trust</li> <li>• Tenovus Cancer Information Centre</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Cancer Physicians</li> <li>• Association of Coloproctologists of Great Britain</li> <li>• Association of Surgeons of Great Britain and Ireland</li> <li>• British Association for Services to the Elderly</li> <li>• British Association of Surgical Oncology</li> <li>• British Geriatrics Society</li> <li>• British Oncological Association (BOA)</li> <li>• British Psychosocial Oncology Society (BPOS)</li> <li>• British Society of Gastroenterology</li> <li>• Cancer Network Pharmacists Forum</li> <li>• Cancer Research UK</li> <li>• Royal College of Anaesthetists</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians, Medical Oncology Joint Special Committee</li> <li>• Royal College of Radiologists</li> <li>• Royal College of Surgeons</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine – Intellectual Disabilities Forum</li> <li>• United Kingdom Clinical Pharmacy Association</li> <li>• United Kingdom Oncology Nursing Society</li> </ul>	<p>folinate, calcium levofolinate)</p> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Bowel &amp; Cancer Research</li> <li>• Institute of Cancer Research</li> <li>• MRC Clinical Trials Unit</li> <li>• National Cancer Research Institute</li> <li>• National Cancer Research Network</li> <li>• National Institute for Health Research</li> <li>• Policy Research Institute on Ageing and Ethnicity</li> <li>• Research Institute for the Care of Older People</li> </ul> <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> <li>• National Institute for Health Research Health Technology Assessment Programme</li> <li>• West Midlands Health Technology Assessment Collaboration</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• National Collaborating Centre for Cancer</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• None</li> </ul>

National Institute for Health and Clinical Excellence

Matrix for the appraisal of bevacizumab in combination with oxaliplatin and either 5FU or capecitabine for the treatment of metastatic colorectal cancer

Consultees	Commentators (no right to submit or appeal)
<u>Others</u> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• Manchester PCT</li> <li>• North Lancashire PCT</li> <li>• Welsh Assembly Government</li> </ul>	

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues

**Definitions:**

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC],

---

<sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.

National Institute for Health and Clinical Excellence

Matrix for the appraisal of bevacizumab in combination with oxaliplatin and either 5FU or capecitabine for the treatment of metastatic colorectal cancer

National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

### Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.